vaccination response to hepatitis B
Conditions
Interventions
The study population will consist of healthy Caucasian male volunteers (age 20-30 yrs.), all receiving food grade ITFs
Frutafit®CLR, Frutafit®TEX! or a placebo (fructose). All in combination with the first shot of the annual hepatitis B vaccination received by these volunteers during their bachelor at the Medical Facu
I) Frutafit®CLR+hepatitis B vaccination, II) Frutafit®TEX!+hepatitis B vaccination, III) placebo (fructose)+hepatitis B vaccination. Blood samples (lithium heparin) will be collected at day 0, 7, 14,
Sponsors
University Medical Center Groningen (UMCG)
(The Netherlands)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age 20-30 yr; 2. Healthy subjects; 3. Male subjects; 4. Written informed consent; 5. Caucasian subjects; 6. Caucasian males; 7. Hepatitis B vaccination; 8. Subjects exposed to patient material; 9. Subjects occupied within the UMCG.
Exclusion criteria
Exclusion criteria: 1. Presence of acute or chronic diseases; 2. Gastrointestinal disorders (e.g. inflammatory bowel disease, celiac disease); 3. Gastrointestinal surgery; 4. Treatment with antibiotics within 6 months of the start of the study; 5. Prior vaccination with hepatitis B; 6. Previous hepatitis B infection; 7. Immunodeficiencies; 8. Use of anti-coagulant drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vaccination titer response to hepatitis B. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in immune cell populations, fecal IgA and short chain fatty acids and microbiota composition. | — |
Contacts
Public ContactP. Vos, de
University Medical Center Groningen (UMCG) Pathology and Medical Biology section Immunoendocrinology Hanzeplein 1, EA 11
Outcome results
None listed